Breakthrough Treatment By Professor Manohar Bance Marks New Era in Auditory Medicine
Opal Sandy from Oxfordshire, once deaf since birth due to a rare genetic condition called auditory neuropathy, has experienced a miraculous transformation. At just 11 months old, she became the first British patient to undergo groundbreaking gene therapy, administered at Addenbrooke’s Hospital in Cambridge. This pioneering treatment has enabled Opal to hear unaided for the first time in her life.
Exploring the Breakthrough:
Auditory neuropathy, caused by a disruption in nerve impulses from the inner ear to the brain, rendered Opal completely deaf at birth. However, within four weeks of receiving gene therapy to her right ear, Opal began responding to sound, even with her left ear’s cochlear implant switched off. Over subsequent weeks, her hearing continued to improve significantly.
Family’s Joyful Revelation:
By the age of 18 months, Opal could respond to her parents’ voices and articulate words such as “Dada” and “bye-bye.” Her mother, Jo Sandy, expressed sheer joy at witnessing Opal’s ability to hear clapping unaided and the confirmation, at 24 weeks, that her daughter’s hearing had reached near-normal levels for soft sounds and speech.
Understanding the Science Behind the Success:
The breakthrough gene therapy targets mutations in the OTOF gene, responsible for producing a protein called otoferlin critical for communication between inner ear hair cells and the hearing nerve. Approximately 20,000 individuals across several countries, including the UK, are affected by deafness caused by this gene mutation.
Significance of the CHORD Trial:
The CHORD trial, initiated in May 2023, aims to evaluate the efficacy of gene therapy in restoring hearing for children with auditory neuropathy. Spearheaded by Professor Manohar Bance from the University of Cambridge, the trial has shown spectacular results, surpassing expectations.
Hope for the Future:
Gene therapy presents a promising alternative to traditional treatments like cochlear implants. Opal’s case heralds a new era in the management of genetic hearing disorders, offering hope to countless families worldwide.
Parental Perspective:
Opal’s father, James Sandy, expresses pride in contributing to such pivotal research, hopeful that it will benefit other children and families facing similar challenges. Opal’s remarkable progress, alongside data from the CHORD trial, is being presented at prestigious scientific forums, signaling a significant step forward in genomic medicine.
Medical Community’s Response:
Dr. Richard Brown, a Consultant Paediatrician involved in the trial, highlights the importance of genomic medicine in providing hope to patients with previously incurable conditions. The CHORD trial, funded by Regeneron, is enrolling patients across multiple countries, with a focus on safety and long-term effectiveness.
Conclusion:
As research in gene therapy advances, the prospect of restoring hearing to those with genetic hearing loss becomes increasingly promising. With ongoing support from research facilities and funding agencies, initiatives like the CHORD trial pave the way for transformative treatments in genomic medicine.
What is the breakthrough treatment Opal Sandy received?
Opal Sandy received groundbreaking gene therapy at Addenbrooke’s Hospital in Cambridge.
What genetic condition left Opal deaf since birth?
Opal was deaf since birth due to auditory neuropathy, a rare genetic condition.
Who spearheaded the CHORD trial?
Professor Manohar Bance from the University of Cambridge spearheaded the CHORD trial.
How did Opal respond to sound after receiving gene therapy?
Opal began responding to sound within four weeks of receiving gene therapy to her right ear.
What protein is crucial for communication between inner ear hair cells and the hearing nerve?
The protein called otoferlin is crucial for communication between inner ear hair cells and the hearing nerve.
How many people are affected by deafness caused by mutations in the OTOF gene?
Approximately 20,000 individuals across several countries are affected by deafness caused by mutations in the OTOF gene.
What is the hope for gene therapy in treating genetic hearing disorders?
Gene therapy presents a promising alternative to traditional treatments like cochlear implants in managing genetic hearing disorders.
Who expressed pride in contributing to pivotal research for gene therapy?
Opal’s father, James Sandy, expressed pride in contributing to pivotal research for gene therapy.
What is the significance of the CHORD trial in genomic medicine?
The CHORD trial signifies a significant step forward in genomic medicine, offering hope to patients with previously incurable conditions.
Who is funding the CHORD trial?
The CHORD trial is funded by Regeneron.
